Elvitegravir vs VH4524184
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV integrase · full HIV pipeline
Elvitegravir · Stribild
Marketed by Gilead Sciences and partners
NCT01095796 · Phase 3 · completed
Participants were randomized and quadruple-blinded to Stribild or active-controlled Atripla, with 348 and 352 treated participants analyzed, respectively. The primary week-48 virologic endpoint met the prespecified non-inferiority criterion, but HIV-1 RNA suppression is a surrogate endpoint rather than a hard clinical or endoscopic outcome.
Reported efficacy
The Percentage of Participants With Virologic Success Using the Food and Drug Administration (FDA)-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 Ribonucleic Acid (RNA) < 50 Copies/mL at Week 48: The Percentage of Participants With Virologic Success Using the Food and Drug Administration (FDA)-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 Ribonucleic Acid (RNA) < 50 Copies/mL at Week 48 (Week 48): Stribild 87.6% vs Atripla 84.1% (met)
Result source: NCT01095796
VH4524184
Developed by ViiV Healthcare
NCT06214052 · Phase 2 · completed
The study was randomized and double-blind with matching placebo, but it was very small, with 6, 6, and 7 participants receiving VH4524184 doses and only 3 receiving placebo. Its primary endpoint was a surrogate measure of plasma HIV-1 RNA change, and although the reported mean changes favored the medium and high doses, statistical significance was not reported.
Next expected readout: October 2027 · NCT07202546 (registry estimate)
Reported efficacy
Monotherapy: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) (At Day 10): Monotherapy: Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) (At Day 10): VH4524184 Dose 1 -1.17 Copies per milliliter (copies/mL) (Standard Deviation 0.46) | VH4524184 Dose 2 -2.15 Copies per milliliter (copies/mL) (Standard Deviation 0.254) | VH4524184 Dose 3 -2.31 Copies per milliliter (copies/mL) (Standard Deviation 0.463) vs Placebo -0.28 Copies per milliliter (copies/mL) (Standard Deviation 0.37) (unclear)
Result source: NCT06214052
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Elvitegravir | VH4524184 |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | 87.6% vs 84.1%vs AtriplaNCT0109579634 other results
| —Not reported |
| HIV-1 RNA 50 copies/mL or more (week 48) | —Not reported | —Not reported |
| CD4 count, change (week 48) | 360 vs 328vs AtriplaNCT0109579626 other results
| —Not reported |
HIV-1 RNA below 50 copies/mL (week 48)
- Elvitegravir
- 87.6% vs 84.1%vs AtriplaNCT01095796
34 other results
- 91.6% vs 88.5% NCT01797445
- 87.2% vs 80.8% NCT01705574
- 93.1% vs 92.8% NCT01780506
- 59% vs 57.8% NCT00708162
- 93.8% vs 87.1% NCT01475838
- 93.4% vs 88.1% NCT01495702
- 89.5% vs 86.8% NCT01106586
- 80.2% vs 75.3% NCT01095796
- 86.9% vs 83.1% NCT01780506
- 77.6% vs 74.6% NCT01106586
- 84.2% vs 81.5% NCT01095796
- 92.8% vs 89.1% NCT01815736
- 84% vs 82.3% NCT01797445
- 89.2% vs 88.2% NCT01780506
- 47.6% vs 45% NCT00708162
- 52.4% vs 53% NCT00708162
- 53.6% vs 56.4% NCT00708162
- 86.9% vs 69.8% NCT01475838
- 86.6% vs 80.4% NCT01495702
- 83.3% vs 82.3% NCT01106586
- 85.9% vs 83.2% NCT01095796
- 88.8% vs 85.5% NCT01095796
- 59.8% vs 57.5% NCT00708162
- 61% vs 60.7% NCT00708162
- 86.1% vs 84.8% NCT01106586
- 91.5% vs 88.5% NCT01106586
- 76.1% vs 78.1% NCT01095796
- 78.4% vs 73.1% NCT01106586
- 88.4% vs 89.7% NCT01497899
- 89.6% vs 87% NCT00869557
- 88.4% vs 87.9% NCT01497899
- 89.6% vs 87% NCT00869557
- 91.7% vs 82.6% NCT00869557
- 89.6% vs 87% NCT00869557
- VH4524184
- —Not reported
HIV-1 RNA 50 copies/mL or more (week 48)
- Elvitegravir
- —Not reported
- VH4524184
- —Not reported
CD4 count, change (week 48)
- Elvitegravir
- 360 vs 328vs AtriplaNCT01095796
26 other results
- 338 vs 340 NCT01106586
- 321 vs 300 NCT01095796
- 323 vs 310 NCT01780506
- 280 vs 293 NCT01106586
- 295 vs 273 NCT01095796
- 60 vs 42 NCT01815736
- 274 vs 260 NCT01797445
- 285 vs 271 NCT01780506
- 205 vs 198 NCT00708162
- 61 vs 71 NCT01475838
- 83 vs 101 NCT01495702
- 256 vs 261 NCT01106586
- 239 vs 206 NCT01095796
- 225 vs 200 NCT01797445
- 221 vs 212 NCT01705574
- 235 vs 221 NCT01780506
- 207 vs 211 NCT01106586
- 56 vs -1 NCT02616783
- 138 vs 147 NCT00708162
- 40 vs 32 NCT01475838
- 56 vs 58 NCT01495702
- 48 vs -4 NCT02616783
- 177 vs 204 NCT01497899
- 240 vs 166 NCT00869557
- 165 vs 179 NCT01497899
- 161 vs 117 NCT00869557
- VH4524184
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Elvitegravir: 4 of 4 rows · VH4524184: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Elvitegravir | VH4524184 |
|---|---|---|
| Dropout rate | 83.6%a NCT01095796 · Phase 3 · monotherapy · HIV · phase 3 show 38 more results22.2% NCT02477527 · Phase 4 · registry result, not featured evidence —DSG Base Study Weeks 24-48 NCT02397096 · Phase 3 · registry result, not featured evidence —DSG Study Extension 1 NCT02397096 · Phase 3 · registry result, not featured evidence —DSG Study Extension 2 NCT02397096 · Phase 3 · registry result, not featured evidence —DSG Study Extension 3 NCT02397096 · Phase 3 · registry result, not featured evidence 6.3%Delayed Switch Group (DSG) NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Base Study Weeks 0-24 NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Base Study Weeks 24-48 NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Study Extension 1 NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Study Extension 2 NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Study Extension 3 NCT02397096 · Phase 3 · registry result, not featured evidence 5.1%Immediate Switch Group (ISG) NCT02397096 · Phase 3 · registry result, not featured evidence 5.1%E/C/F/TAF NCT01815736 · Phase 3 · registry result, not featured evidence —Extension Phase: E/C/F/TAF From E/ NCT01815736 · Phase 3 · registry result, not featured evidence —Extension Phase: E/C/F/TAF From SB NCT01815736 · Phase 3 · registry result, not featured evidence —Randomized Phase: E/C/F/TAF NCT01815736 · Phase 3 · registry result, not featured evidence 20%E/C/F/TAF NCT01797445 · Phase 3 · registry result, not featured evidence —E/C/F/TAF (Double-Blind Phase) NCT01797445 · Phase 3 · registry result, not featured evidence —Open-Label E/C/F/TAF From E/C/F/TA NCT01797445 · Phase 3 · registry result, not featured evidence —Open-Label E/C/F/TAF From E/C/F/TD NCT01797445 · Phase 3 · registry result, not featured evidence —DB STB to OL STB NCT01705574 · Phase 3 · registry result, not featured evidence —Double-Blind: STB NCT01705574 · Phase 3 · registry result, not featured evidence 5.4% NCT02616783 · Phase 3 · registry result, not featured evidence —Double-Blind: E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 16%E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —Open-Label: E/C/F/TAF to E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 43.2% NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 12.3%COBI+PI+2 NRTIs (Cohort 2) NCT01363011 · Phase 3 · registry result, not featured evidence · combination 12.1%E/C/F/TDF (Cohort 1) NCT01363011 · Phase 3 · registry result, not featured evidence · combination 10.2% NCT01475838 · Phase 3 · registry result, not featured evidence —All Stribild NCT01495702 · Phase 3 · registry result, not featured evidence 8.9%Stribild NCT01495702 · Phase 3 · registry result, not featured evidence —Stribild (Randomized Phase) NCT01495702 · Phase 3 · registry result, not featured evidence 80.7% NCT01106586 · Phase 3 · registry result, not featured evidence 0% NCT01533259 · Phase 3 · registry result, not featured evidence 14% NCT01721109 · Phase 2/3 · registry result, not featured evidence 5.3% NCT01497899 · Phase 2 · registry result, not featured evidence 6.3% NCT00869557 · Phase 2 · registry result, not featured evidence | 0%Dose 1 NCT06214052 · Phase 2 · combination · HIV · phase 2 show 8 more results—Dose 1 NCT06214052 · Phase 2 · combination · HIV · phase 2 —Dose 1 NCT06214052 · Phase 2 · combination · HIV · phase 2 0%Dose 2 NCT06214052 · Phase 2 · combination · HIV · phase 2 —Dose 2 NCT06214052 · Phase 2 · combination · HIV · phase 2 —Dose 2 NCT06214052 · Phase 2 · combination · HIV · phase 2 0%Dose 3 NCT06214052 · Phase 2 · combination · HIV · phase 2 —Dose 3 NCT06214052 · Phase 2 · combination · HIV · phase 2 —Dose 3 NCT06214052 · Phase 2 · combination · HIV · phase 2 |
| Discontinued due to AEs | 2.5%a NCT01095796 · Phase 3 · monotherapy · HIV · phase 3 show 38 more results— NCT02477527 · Phase 4 · registry result, not featured evidence —DSG Base Study Weeks 24-48 NCT02397096 · Phase 3 · registry result, not featured evidence —DSG Study Extension 1 NCT02397096 · Phase 3 · registry result, not featured evidence —DSG Study Extension 2 NCT02397096 · Phase 3 · registry result, not featured evidence —DSG Study Extension 3 NCT02397096 · Phase 3 · registry result, not featured evidence 0.4%Delayed Switch Group (DSG) NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Base Study Weeks 0-24 NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Base Study Weeks 24-48 NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Study Extension 1 NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Study Extension 2 NCT02397096 · Phase 3 · registry result, not featured evidence —ISG Study Extension 3 NCT02397096 · Phase 3 · registry result, not featured evidence 1.6%Immediate Switch Group (ISG) NCT02397096 · Phase 3 · registry result, not featured evidence 0.7%E/C/F/TAF NCT01815736 · Phase 3 · registry result, not featured evidence —Extension Phase: E/C/F/TAF From E/ NCT01815736 · Phase 3 · registry result, not featured evidence —Extension Phase: E/C/F/TAF From SB NCT01815736 · Phase 3 · registry result, not featured evidence —Randomized Phase: E/C/F/TAF NCT01815736 · Phase 3 · registry result, not featured evidence 0.7%E/C/F/TAF NCT01797445 · Phase 3 · registry result, not featured evidence —E/C/F/TAF (Double-Blind Phase) NCT01797445 · Phase 3 · registry result, not featured evidence —Open-Label E/C/F/TAF From E/C/F/TA NCT01797445 · Phase 3 · registry result, not featured evidence —Open-Label E/C/F/TAF From E/C/F/TD NCT01797445 · Phase 3 · registry result, not featured evidence —DB STB to OL STB NCT01705574 · Phase 3 · registry result, not featured evidence —Double-Blind: STB NCT01705574 · Phase 3 · registry result, not featured evidence 0.9% NCT02616783 · Phase 3 · registry result, not featured evidence —Double-Blind: E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 0.9%E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —Open-Label: E/C/F/TAF to E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 2.2% NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 4.1%COBI+PI+2 NRTIs (Cohort 2) NCT01363011 · Phase 3 · registry result, not featured evidence · combination 6.1%E/C/F/TDF (Cohort 1) NCT01363011 · Phase 3 · registry result, not featured evidence · combination 2% NCT01475838 · Phase 3 · registry result, not featured evidence —All Stribild NCT01495702 · Phase 3 · registry result, not featured evidence 0.7%Stribild NCT01495702 · Phase 3 · registry result, not featured evidence —Stribild (Randomized Phase) NCT01495702 · Phase 3 · registry result, not featured evidence 2.5% NCT01106586 · Phase 3 · registry result, not featured evidence — NCT01533259 · Phase 3 · registry result, not featured evidence — NCT01721109 · Phase 2/3 · registry result, not featured evidence 0.9% NCT01497899 · Phase 2 · registry result, not featured evidence — NCT00869557 · Phase 2 · registry result, not featured evidence | —Dose 1 NCT06214052 · Phase 2 · combination · HIV · phase 2 show 8 more results—Dose 1 NCT06214052 · Phase 2 · combination · HIV · phase 2 —Dose 1 NCT06214052 · Phase 2 · combination · HIV · phase 2 —Dose 2 NCT06214052 · Phase 2 · combination · HIV · phase 2 —Dose 2 NCT06214052 · Phase 2 · combination · HIV · phase 2 —Dose 2 NCT06214052 · Phase 2 · combination · HIV · phase 2 —Dose 3 NCT06214052 · Phase 2 · combination · HIV · phase 2 —Dose 3 NCT06214052 · Phase 2 · combination · HIV · phase 2 —Dose 3 NCT06214052 · Phase 2 · combination · HIV · phase 2 |
| Serious AEs | 19.8%a NCT01095796 · Phase 3 · monotherapy · HIV · phase 3 show 38 more results0% NCT02477527 · Phase 4 · registry result, not featured evidence 1.9%DSG Base Study Weeks 24-48 NCT02397096 · Phase 3 · registry result, not featured evidence 6.4%DSG Study Extension 1 NCT02397096 · Phase 3 · registry result, not featured evidence 4.5%DSG Study Extension 2 NCT02397096 · Phase 3 · registry result, not featured evidence 2.3%DSG Study Extension 3 NCT02397096 · Phase 3 · registry result, not featured evidence —Delayed Switch Group (DSG) NCT02397096 · Phase 3 · registry result, not featured evidence 2.9%ISG Base Study Weeks 0-24 NCT02397096 · Phase 3 · registry result, not featured evidence 2.6%ISG Base Study Weeks 24-48 NCT02397096 · Phase 3 · registry result, not featured evidence 9.3%ISG Study Extension 1 NCT02397096 · Phase 3 · registry result, not featured evidence 4.3%ISG Study Extension 2 NCT02397096 · Phase 3 · registry result, not featured evidence 3.6%ISG Study Extension 3 NCT02397096 · Phase 3 · registry result, not featured evidence —Immediate Switch Group (ISG) NCT02397096 · Phase 3 · registry result, not featured evidence —E/C/F/TAF NCT01815736 · Phase 3 · registry result, not featured evidence 3%Extension Phase: E/C/F/TAF From E/ NCT01815736 · Phase 3 · registry result, not featured evidence 5.2%Extension Phase: E/C/F/TAF From SB NCT01815736 · Phase 3 · registry result, not featured evidence 8.2%Randomized Phase: E/C/F/TAF NCT01815736 · Phase 3 · registry result, not featured evidence —E/C/F/TAF NCT01797445 · Phase 3 · registry result, not featured evidence 12.5%E/C/F/TAF (Double-Blind Phase) NCT01797445 · Phase 3 · registry result, not featured evidence 2.8%Open-Label E/C/F/TAF From E/C/F/TA NCT01797445 · Phase 3 · registry result, not featured evidence 1.7%Open-Label E/C/F/TAF From E/C/F/TD NCT01797445 · Phase 3 · registry result, not featured evidence 5.3%DB STB to OL STB NCT01705574 · Phase 3 · registry result, not featured evidence 8.7%Double-Blind: STB NCT01705574 · Phase 3 · registry result, not featured evidence 9.1% NCT02616783 · Phase 3 · registry result, not featured evidence 16.8%Double-Blind: E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 0%Open-Label: E/C/F/TAF to E/C/F/TAF NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 20.6% NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 15.1%COBI+PI+2 NRTIs (Cohort 2) NCT01363011 · Phase 3 · registry result, not featured evidence · combination 18.2%E/C/F/TDF (Cohort 1) NCT01363011 · Phase 3 · registry result, not featured evidence · combination 8.2% NCT01475838 · Phase 3 · registry result, not featured evidence 8.9%All Stribild NCT01495702 · Phase 3 · registry result, not featured evidence —Stribild NCT01495702 · Phase 3 · registry result, not featured evidence 8.2%Stribild (Randomized Phase) NCT01495702 · Phase 3 · registry result, not featured evidence 16.4% NCT01106586 · Phase 3 · registry result, not featured evidence 2.1% NCT01533259 · Phase 3 · registry result, not featured evidence 10% NCT01721109 · Phase 2/3 · registry result, not featured evidence 10.7% NCT01497899 · Phase 2 · registry result, not featured evidence 4.2% NCT00869557 · Phase 2 · registry result, not featured evidence | —Dose 1 NCT06214052 · Phase 2 · combination · HIV · phase 2 show 8 more results0%Dose 1 NCT06214052 · Phase 2 · combination · HIV · phase 2 0%Dose 1 NCT06214052 · Phase 2 · combination · HIV · phase 2 —Dose 2 NCT06214052 · Phase 2 · combination · HIV · phase 2 0%Dose 2 NCT06214052 · Phase 2 · combination · HIV · phase 2 0%Dose 2 NCT06214052 · Phase 2 · combination · HIV · phase 2 —Dose 3 NCT06214052 · Phase 2 · combination · HIV · phase 2 0%Dose 3 NCT06214052 · Phase 2 · combination · HIV · phase 2 0%Dose 3 NCT06214052 · Phase 2 · combination · HIV · phase 2 |
| Most frequent reported AEs | a diarrhoea 26.7% upper respiratory tract infection 26.4% nausea 23% NCT01095796 · Phase 3 · monotherapy · HIV · phase 3 show 31 more resultsheadache 6.7% diarrhoea 4.3% nasopharyngitis 4.3% NCT02397096 · Phase 3 · registry result, not featured evidence nasopharyngitis 14.4% headache 6.4% diarrhoea 5.4% NCT02397096 · Phase 3 · registry result, not featured evidence covid-19 3.9% headache 1.9% back pain 1.3% NCT02397096 · Phase 3 · registry result, not featured evidence nasopharyngitis 7.4% headache 6.5% diarrhoea 4.5% NCT02397096 · Phase 3 · registry result, not featured evidence nasopharyngitis 4.4% back pain 3.7% diarrhoea 3% NCT02397096 · Phase 3 · registry result, not featured evidence nasopharyngitis 12.8% headache 5.5% arthralgia 5.3% NCT02397096 · Phase 3 · registry result, not featured evidence back pain 2.3% arthralgia 1.7% nasopharyngitis 1.7% NCT02397096 · Phase 3 · registry result, not featured evidence covid-19 8.3% arthralgia 1.2% diarrhoea 1.2% NCT02397096 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 7.4% nasopharyngitis 5.2% diarrhoea 4.4% NCT01815736 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 6.1% diarrhoea 5.2% nasopharyngitis 4.7% NCT01815736 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 17.5% diarrhoea 11.4% nasopharyngitis 10% NCT01815736 · Phase 3 · registry result, not featured evidence diarrhoea 23% headache 22.7% upper respiratory tract infection 20.2% NCT01797445 · Phase 3 · registry result, not featured evidence nasopharyngitis 3.5% headache 2.8% arthralgia 1.4% NCT01797445 · Phase 3 · registry result, not featured evidence nasopharyngitis 4.2% cough 2.5% syphilis 2.5% NCT01797445 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 14.6% headache 11% anaemia 7.3% NCT01705574 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 17.3% headache 17% nausea 14.9% NCT01705574 · Phase 3 · registry result, not featured evidence nasopharyngitis 10.9% back pain 8.2% diarrhoea 7.3% NCT02616783 · Phase 3 · registry result, not featured evidence diarrhoea 25.7% upper respiratory tract infection 21.1% nausea 16.8% NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 cough 4.4% syphilis 4.4% upper respiratory tract infection 3.3% NCT01780506 · Phase 3 · registry result, not featured evidence · HIV · phase 3 diarrhoea 33.9% upper respiratory tract infection 21.2% headache 13.8% NCT00708162 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 upper respiratory tract infection 20.5% nasopharyngitis 19.2% bronchitis 13.7% NCT01363011 · Phase 3 · registry result, not featured evidence · combination diarrhoea 36.4% insomnia 21.2% headache 18.2% NCT01363011 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 13.3% upper respiratory tract infection 9.9% diarrhoea 9.2% NCT01475838 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 11.3% diarrhoea 10.2% nasopharyngitis 10.2% NCT01495702 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 11.3% diarrhoea 10.3% nasopharyngitis 10.3% NCT01495702 · Phase 3 · registry result, not featured evidence diarrhoea 28% upper respiratory tract infection 24.4% nausea 22.7% NCT01106586 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 20.8% insomnia 12.5% anxiety 10.4% NCT01533259 · Phase 3 · registry result, not featured evidence upper respiratory tract infection 36% headache 24% vomiting 20% NCT01721109 · Phase 2/3 · registry result, not featured evidence nausea 22.3% diarrhoea 17% fatigue 16.1% NCT01497899 · Phase 2 · registry result, not featured evidence diarrhoea 27.1% fatigue 16.7% headache 14.6% NCT00869557 · Phase 2 · registry result, not featured evidence | Dose 1 abdominal distension 16.7% (placebo 0%) acute sinusitis 16.7% (placebo 0%) dermatitis 16.7% (placebo 0%) NCT06214052 · Phase 2 · combination · HIV · phase 2 show 5 more resultsDose 1 dermatitis 16.7% (placebo 0%) diarrhoea 16.7% (placebo 33.3%) abdominal distension 0% (placebo 0%) NCT06214052 · Phase 2 · combination · HIV · phase 2 Dose 2 alanine aminotransferase increased 16.7% (placebo 0%) gastroenteritis 16.7% (placebo 33.3%) hypertension 16.7% (placebo 0%) NCT06214052 · Phase 2 · combination · HIV · phase 2 Dose 2 amylase increased 16.7% (placebo 0%) fatigue 16.7% (placebo 0%) lipase increased 16.7% (placebo 0%) NCT06214052 · Phase 2 · combination · HIV · phase 2 Dose 3 abdominal distension 14.3% (placebo 0%) diarrhoea 14.3% (placebo 33.3%) dyspepsia 14.3% (placebo 0%) NCT06214052 · Phase 2 · combination · HIV · phase 2 Dose 3 dizziness 14.3% (placebo 0%) headache 14.3% (placebo 66.7%) influenza like illness 14.3% (placebo 0%) NCT06214052 · Phase 2 · combination · HIV · phase 2 |
Notes
- aPopulation comparability has not been reviewed for 34 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Elvitegravir
show 34 more results
show 2 more results
show 3 more results
show 1 more result
show 1 more result
show 3 more results
show 3 more results
show 1 more result
show 5 more results
+ 14 further endpoints in the CSV export.
VH4524184
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Elvitegravir's landscape · VH4524184's landscape